Novacyt confirms IVDR accreditation under the new EU regulation requirements for in vitro diagnostic medical devices (IVDR) for its DPYD test, making it one of the first products of its kind to comply with the new IVDR requirements.

The clinical diagnostics company states that this genotyping test 'enables the identification of cancer patients at risk of suffering a severe, and potentially life-threatening, reaction to common chemotherapy'.

The Yourgene DPYD test is used to identify patients with dihydropyrimidine dehydrogenase (DPD) enzyme deficiency, through the rapid detection of six clinically relevant variants of the DPD enzyme.

Copyright (c) 2023 CercleFinance.com. All rights reserved.